More than a decade ago, Yale chemist Craig Crews founded a biotechnology company in New Haven based on his pioneering research into PROTACs (or PROteolysis TArgeting Chimera), a technology that treats certain types of cancer and other diseases by degrading the proteins that cause them.
Technology receives FDA approval for breast cancer treatment
